Posted by Michael Wonder on 03 May 2023
Memo Therapeutics receives FDA fast track designation for AntiBKV as treatment of BKV infection in renal transplant patients
2 May 2023 - Memo Therapeutics announced today that the US FDA has granted fast track designation to AntiBKV, MTx’s lead antibody therapeutic that targets BK polyomavirus infection commonly seen in renal transplant patients.
AntiBKV has successfully completed a phase I clinical study and following FDA clearance has started actively recruiting patients for a pivotal phase II/III clinical trial.
